ICU Medical (NASDAQ:ICUI) Rating Increased to Strong-Buy at BTIG Research

BTIG Research upgraded shares of ICU Medical (NASDAQ:ICUI) to a strong-buy rating in a report published on Monday,Zacks.com reports.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings upgraded shares of ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. KeyCorp cut their target price on ICU Medical from $180.00 to $164.00 and set an “overweight” rating on the stock in a research note on Monday, April 27th. Sanford C. Bernstein downgraded ICU Medical to a “market perform” rating in a research report on Monday. Needham & Company LLC upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research report on Wednesday, May 27th. Finally, Piper Sandler lowered their price target on ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, ICU Medical has a consensus rating of “Buy” and an average target price of $168.40.

ICU Medical Trading Up 1.1%

NASDAQ ICUI opened at $143.72 on Monday. ICU Medical has a 52 week low of $107.00 and a 52 week high of $160.29. The stock has a market cap of $3.59 billion, a P/E ratio of 77.69, a PEG ratio of 1.99 and a beta of 0.77. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60. The company’s fifty day simple moving average is $128.53 and its 200-day simple moving average is $138.66.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share for the quarter, beating analysts’ consensus estimates of $1.78 by $0.19. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The company had revenue of $525.77 million during the quarter, compared to analysts’ expectations of $520.65 million. During the same period in the prior year, the company posted $1.72 EPS. The firm’s revenue for the quarter was down 12.3% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Equities research analysts predict that ICU Medical will post 6.5 EPS for the current fiscal year.

Insider Activity at ICU Medical

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,447 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the sale, the vice president directly owned 19,460 shares of the company’s stock, valued at $2,414,596.80. The trade was a 11.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of the stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the sale, the director owned 7,960 shares of the company’s stock, valued at $978,363.60. The trade was a 23.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

Institutional investors have recently bought and sold shares of the business. Hilton Head Capital Partners LLC purchased a new position in ICU Medical during the 4th quarter valued at about $32,000. Covestor Ltd lifted its position in shares of ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 126 shares in the last quarter. Strs Ohio boosted its holdings in shares of ICU Medical by 60.0% during the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after purchasing an additional 300 shares during the period. Rockefeller Capital Management L.P. grew its position in ICU Medical by 21.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 146 shares in the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in ICU Medical during the fourth quarter valued at approximately $120,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.